NEU 0.35% $20.17 neuren pharmaceuticals limited

Pending ROW deal??, page-175

  1. 2,167 Posts.
    lightbulb Created with Sketch. 571
    Trof/DAYBUE is very profitable business on low numbers.

    US population identified 5,000, at 3,000 patients @ $375k p/p its block buster status drug US$1.12bn in sales to Acadia.

    ROW population 7,000 would be great to achieve 3,000 however at 2,000 patients @ $375k p/p ist US$750k in sales to ROW partner.

    US deal was originally attractive for Acadia on US$500m peak sales so ROW market is very attractive.

    IF NEU can get higher % royalties for ROW then conservative example would be;

    As a whole Global patients 5,000 @ $375k p/p = US$1.8bn - 15% royalty = US$281m or $420m AUD to NEU + sales milestones x 2 US$300m or $448mAUD total combined revenue to NEU $868mAUD (approx AUD$520m net profit)

    $520m net profit = EPS 4 x 20 P/E = $80p/sh

    Very lucrativeairly for all involved with conservative patient numbers as only using approx 40% of the global 12,000 identified patients, I have no doubt identified globally patients will increase particularly due to better diagnosis now and broad labelling of DAYBUE in US alone.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.